|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00108563 |
The purpose of this study is to learn more about the effects of interferon and ribavirin combination therapy in people with Hepatitis C. The specific aims are:
Condition | Intervention | Phase |
Hepatitis C Depression |
Drug: Citalopram or Placebo |
Phase IV |
MedlinePlus related topics: | Antidepressants Depression Hepatitis Hepatitis C |
ChemIDplus related topics: | Ribavirin Escitalopram Benzetimide Citalopram Citalopram hydrobromide Dexetimide Escitalopram oxalate Interferon alfa-n1 Interferon alfa-2a Interferon alfa-2b Interferons |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | VISN 20 Prophylactic Treatment of IFN-Induced Depression in Hepatitis C |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CLIN-012-02S |
First Received: | April 15, 2005 |
Last Updated: | March 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00108563 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|